Why the study?
Does orthotopic lung transplantation with immunosuppression in mice induce obliterative bronchiolitis lesions resembling human chronic rejection?
Does orthotopic lung transplantation with immunosuppression in mice induce obliterative bronchiolitis lesions resembling human chronic rejection?
This study establishes a murine model of chronic rejection after orthotopic lung transplantation that develops obliterative bronchiolitis lesions, though it highlights that pulmonary function testing is inadequate for diagnosing chronic rejection in mice.
Pulmonary function testing should not guide chronic rejection assessment in this murine model; leaves open histologic endpoints for future allograft studies.
Almost all animal models for chronic rejection (CR) after lung transplantation (LTx) fail to resemble the human situation. It was our attempt to develop a representative model of CR in mice. Orthotopic LTx was performed in allografts receiving daily immunosuppression with steroids and cyclosporine. Controls included isografts and mice only undergoing thoracotomy (SHAM). Allografts were sacrificed 2, 4, 6, 8, 10 or 12 weeks after LTx. Pulmonary function was measured repeatedly in the 12w allografts, isografts and SHAM mice. Histologically, all allografts demonstrated acute rejection (AR) around the blood vessels and airways two weeks after LTx. This decreased to 50-75% up to 10 weeks and was absent after 12 weeks. Obliterative bronchiolitis (OB) lesions were observed in 25-50% of the mice from 4-12 weeks. Isografts and lungs of SHAM mice were normal after 12 weeks. Pulmonary function measurements showed a decline in FEV(0.1), TLC and compliance in the allografts postoperatively (2 weeks) with a slow recovery over time. After this initial decline, lung function of allografts increased more than in isografts and SHAM mice indicating that pulmonary function measurement is not a good tool to diagnose CR in a mouse. We conclude that a true model for CR, with clear OB lesions in about one third of the animals, but without a decline in lung function, is possible. This model is an important step forward in the development of an ideal model for CR which will open new perspectives in unraveling CR pathogenesis and exploring new treatment options.
No takes yet. Share an insight, caveat, or question.
Vleeschauwer et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: